Objectives: We aimed to retrospectively evaluate the impact of 18[F] fluorodeoxy-glucose-positron emission tomography (FDG-PET) to detect recurrent breast cancer based on asymptomatically elevated tumor marker levels. Methods: Whole-body FDG-PET was performed on 20 patients suspected of recurrent breast cancer who had increase in asymptomatic tumor markers but with normal imaging modality results. A blood sample was drawn in each case for marker assay (CA15-3 and CEA) on the same day the FDG-PET was to be performed. All of the 20 asymptomatic patients had either a CA15-3>32U/mL or a CEA>5ng/mL. The final diagnosis of recurrent breast cancer was established by operation/biopsy, histopathological findings, or by additional morphologic imaging techniques during clinical follow-up more than l year after initial diagnosis. Results: The final diagnosis of recurrent breast cancer was established in 30 sites of 19 patients. FDG-PET accurately detected 29/30 sites in 18/19 patients with recurrence. The diagnostic sensitivity and accuracy of FDG-PET in patients with suspected recurrent breast cancer and asymptomatically elevated tumor markers were 94.7% and 90.0%, respectively. Conclusions: FDG-PET is a useful technique for detecting recurrent breast cancer suspected by asymptomatically elevated tumor markers levels and has an important clinical impact on the management of these patients.
Objectives: We aimed to retrospectively evaluate the impact of 18[F] fluorodeoxy-glucose-positron emission tomography (FDG-PET) to detect recurrent breast cancer based on asymptomatically elevated tumor marker levels. Methods: Whole-body FDG-PET was performed on 20 patients suspected of recurrent breast cancer who had increase in asymptomatic tumor markers but with normal imaging modality results. A blood sample was drawn in each case for marker assay (CA15-3 and CEA) on the same day the FDG-PET was to be performed. All of the 20 asymptomatic patients had either a CA15-3>32U/mL or a CEA>5ng/mL. The final diagnosis of recurrent breast cancer was established by operation/biopsy, histopathological findings, or by additional morphologic imaging techniques during clinical follow-up more than l year after initial diagnosis. Results: The final diagnosis of recurrent breast cancer was established in 30 sites of 19 patients. FDG-PET accurately detected 29/30 sites in 18/19 patients with recurrence. The diagnostic sensitivity and accuracy of FDG-PET in patients with suspected recurrent breast cancer and asymptomatically elevated tumor markers were 94.7% and 90.0%, respectively. Conclusions: FDG-PET is a useful technique for detecting recurrent breast cancer suspected by asymptomatically elevated tumor markers levels and has an important clinical impact on the management of these patients.
為了持續優化網站功能與使用者體驗,本網站將Cookies分析技術用於網站營運、分析和個人化服務之目的。
若您繼續瀏覽本網站,即表示您同意本網站使用Cookies。